Replies to post #35665 on RespireRx Pharmaceuticals Inc (fka RSPI)

[haysaw]

Cortex must have been so excited about the news, that they forgot to plan/include a conference call in the PR, to further enlighten shareholders about our bright future...

[enemem]

The most plausible course of action IMO is to focus on the patient population already chronically using opioids to manage pain. This patient population has big problems with SA, and because of the sedative effect of the opioids, probably will fall asleep anyway.

If corx could sign a deal to develop an opioid-ampakine combo for pain management, which dramatically reduces morbidity / mortality due to SA and/or RD, they'd have a very nice payday.

[Aiming4]

Gfp - in regards to the sleep reduction, and I'm just spitballin' here, but I'd guess that patients with SA sleep longer than "normal" to make up for the disruptive sleep they get during the night.

So maybe - maybe - the sleep reduction caused by an ampakine would still result in a more restful / restorative sleep than a longer sleep duration but one disrupted by SA.

Also maybe over time the body would adjust to the presence of an ampakine in terms of sleep duration and the insomnia effect would grow smaller.

[Aiming4]

I'd be amazed if Cortex could get the RD rights back - first off, Cortex doesn't have any money to pay for them... and due to sheer human nature, Valeant would be reluctant to let them go for a lot less than they just paid for them.

I'd also question the benefit of spending much to get the RD rights back... RD was difficult to sell, most here seem to agree that even if viewed as promising, these SA results aren't going to bring a deal - so RD and SA combined don't seem to add up to a package that would be very marketable either.